JAAD International · 2024 · 14 citations · 22 references
Life SciencesDermatologyPharmacotherapyAutoimmunityClinical ImmunologyImmunotherapyAllergic Skin DiseasesAtopic DermatitisAtopic Dermatitis PharmacotherapyAtopic Dermatitis PhototherapyAtopic Dermatitis TreatmentCombination PhototherapyComorbidity AnalysisDermatologic Adverse EventsReal-world Comparative Effectiveness
Background: Dupilumab is a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (MtS-AD). Various clinical trials have established the effectiveness and safety of dupilumab for the treatment MtS-AD; however, the real-world experiences of patients treated with dupilumab with malignancy and other comorbidities are lacking. Objective: To assess the real-life effectiveness and safety of dupilumab in the treatment of MtS-AD within Canadian adult patient population, including those with other significant comorbidities such as malignancy. Methods: In this retrospective study, records of adult patients diagnosed with MtS-AD, with a Physician Global Assessment (PGA) score of 3 or 4, and treated with dupilumab for 52 weeks were reviewed and collected. Results: A total of 155 adult patients with atopic dermatitis (AD) treated with dupilumab were included in the study. Asthma was the most common comorbidity. One hundred twenty-three (80%) patients received either phototherapy and/or at least 1 systemic agent (methotrexate and cyclosporine) before initiation of dupilumab. PGA score of 0 or 1 was achieved by 64% of patients at week 52. Adverse effects including injection site reactions, ocular surface disease, facial and neck redness, and arthropathy occurred in 6%, 10%, 8%, and 6% of patients, respectively. Three patients continued receiving dupilumab throughout pregnancy, all maintaining PGA score of 0 or 1 with no impact on pregnancy, delivery, or the newborn. Twelve patients with prior or active malignancy were included, with no reported negative impact on malignancy. Conclusion: Dupilumab is an effective and safe option for patients with AD in real life, including patients with malignancy and other medical comorbidities.
22
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text
Medicine, Dermatology, Immunology +17
Diamant Thaçi, Eric L. Simpson, Mette Deleuran et al. · Journal of Dermatological Science · 2019 · 185 citations · Full text
Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker et al. · Allergy · 2019 · 149 citations · Full text
Eustachio Nettis, Michela Ortoncelli, Giovanni Pellacani et al. · Journal of Investigational Allergology and Clinical Immunology · 2020 · 65 citations · Full text
Dong Hyek Jang, Seok‐Jae Heo, Hye Jung Jung et al. · Journal of Clinical Medicine · 2020 · 52 citations · Full text